ImmuneOnco to Present at 2021 BIO Digital

Shanghai, China, June 10, 2021 – ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced today that it was selected to present at 2021 BIO Digital, the premier biotech event. BIO Digital is scheduled at June 10-11 & 14-18, 2021. ......

2021-06-11

ImmuneOnco to report Phase I results of IMM01 on ASCO 2021

On April 26, 2021, Shanghai, China, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announces that Phase I results of its key product IMM01 is going to be declared on the annual meeting of the American Society of Clinical Oncology (ASCO) in 2021.The l......

2021-04-26

ImmuneOnco to collaborate with Sunshine Guojian in clinical study of inetetamab (CipterbinTM) in combination with IMM01

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. . (hereinafter referred to as ImmuneOnco ) announced collaboration with Sunshine pharmaceuticals (Shanghai) co., Ltd., a subsidiary of Sunshine Pharmaceutical Group (hereinafter referred to as Sunshine Guo......

2021-04-22

Ground Breaking Ceremony of New building for ImmuneOnco R&D Centre

On March31, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the building for R&D center, located in Lane 100, Banxia Road, Zhoupu, Shanghai (Cell Industrial Park), was officially commenced. The new R&......

2021-04-22

ImmuneOnco announces the appointment of Dr. Kathy Yu as Vice President of the Company

On March 30, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced the appointment of Dr. Kathy Yu as Vice President of the Company, with overall responsibility for the Company's BD affairs. Dr.Yu Xiaoxu g......

2021-04-22